Cetuximab in advanced non-small cell lung cancer

Keyphrases

• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Cetuximab 100%
• Response Rate 42%
• Epidermal Growth Factor Receptor 42%
• Chemotherapy 42%
• Metastatic Non-small Cell Lung Cancer 28%
• Docetaxel 28%
• Phosphorylation 14%
• Molecular Mechanism 14%
• Tumor Growth 14%
• Monotherapy 14%
• Cell Proliferation 14%
• Monoclonal Antibody 14%
• Extracellular Domain 14%
• Angiogenesis 14%
• Ligand Binding 14%
• Non-small Cell Lung Cancer (NSCLC) 14%
• Response Predictors 14%
• Receptor Activation 14%
• Apoptosis Inhibition 14%
• Inhibit Tumor 14%
• Previously Untreated 14%
• Cell Inhibition 14%
• Agent Behavior 14%
• C225 14%
• Erbitux 14%
• Recurrent Non-small Cell Lung Cancer 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Cetuximab 100%
• Chemotherapy 33%
• Epidermal Growth Factor Receptor 33%
• Docetaxel 22%
• Tumor Growth 11%
• Monotherapy 11%
• Monoclonal Antibody 11%